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Abstract The ergot alkaloid bromocriptine (BKT) was found to 
act as a strong inhibitor of purified neuronal nitric oxide synthase 
(NOS) (IC5 0 = 10 ± 2 (iM) whereas it was poorly active towards 
inducible macrophage N O S (IC5 0 > 100 uM). BKT affects the 
activation of N O S by calmodulin, as it not only inhibits L-
arginine oxidation to NO and L-citrulline but also NADPH 
oxidation and cahnodulin-dependent cytochrome c reduction 
catalyzed by neuronal NOS. These results suggest that BKT 
could exert some of its therapeutic effects by interfering with the 
NOS-dependent formation of nitric oxide and/or superoxide ion 
in various tissues. 
© 1997 Federation of European Biochemical Societies. 
Key words: Bromocriptine; Nitric oxide synthase; Selective 
inhibitor; Prolactin; Migraine; Parkinson's disease 
1. Introduction 
The semi-synthetic ergot alkaloid bromocriptine (BKT) 
(Fig. 1) exhibits several therapeutic effects [1-3]: (i) it has a 
beneficial effect in severely disabled patients suffering from 
Parkinson's disease [4], (ii) it is used, like other ergot alka-
loids, in the treatment of migraine, and (iii) it is a strong 
inhibitor of prolactin formation [5]. These effects have been 
related to its ability to block dopamine receptors, and to its 
interaction with calmodulin-induced activation of phospho-
diesterases in rat and human brain [6,7]. 
Calmodulin (CaM) is a ubiquitous calcium binding protein 
which mediates a variety of biological functions [8]. One of 
the most important neuronal mechanisms activated by the 
C a 2 + / C a M system in the brain is the recently discovered bio-
synthesis of nitric oxide (NO). N O displays various functions 
as a cellular messenger in central and peripheral nervous sys-
tems, regulator of vascular tone and platelet aggregation, and 
cytotoxic agent [9,10]. Nitric oxide is produced by constitu-
tive, Ca 2 + /CaM-dependent , neuronal and endothelial nitric 
oxide synthases (nNOS and eNOS), and by inducible NOSs 
(iNOS) that are weakly affected by Ca 2 + but induced by lip-
opolysaccharides (LPS) and cytokines [11]. NOSs are heme-
thiolate proteins which catalyze the five-electron oxidation of 
L-arginine (L-arg) to N O and L-citrulline (L-cit). All NOSs 
Corresponding author. Fax: (33) 01 42 86 83 87. 
Abbreviations: BKT, bromocriptine; CaM, calmodulin; NO, nitric 
oxide; NOS, nitric oxide synthase; nNOS, neuronal NOS; eNOS, 
endothelial NOS; iNOS, inducible NOS; L-arg, L-arginine; L-cit, L-
citrulline; BH4, tetrahydrobiopterin; N02Arg, A^-nitro-L-arginine; 
DTT, dithiothreitol; HEPES, 4-(2-hydroxyethyl)-l-piperazine ethane-
sulfonic acid; EDTA, ethylene diamine tetraacetic acid; EGTA, 
ethylene glycol bis([S-aminoethyl ether) JV,Ar,./V',Ar'-tetraacetic acid; 
Cyt c, cytochrome c; LPS, lipopolysaccharide; FCS, fetal calf serum 
contain two domains separated by a C a M binding site: a C-
terminal reductase domain that binds N A D P H , F A D and 
F M N and exhibits a high sequence identity to cytochrome 
P450 reductases, and an N-terminal oxygenase domain that 
binds heme, tetrahydrobiopterin (BH4) and L-arg [12]. In fact, 
NOSs catalyze three kinds of reactions: (i) the reduction of 
electron acceptors such as cytochrome c (Cyt c) by N A D P H 
that only requires the reductase domain and C a 2 + / C a M for 
maximal activity, (ii) the reduction of dioxygen by N A D P H 
and (iii) the oxidation of L-arg to N O and L-cit by N A D P H 
and 0 2 that are mediated by the heme moiety and require 
complete NOS [13-17]. Contrary to n N O S and eNOS, the 
activity of iNOS is almost independent of Ca 2 + and C a M as 
it binds C a M with a very high affinity [10,11]. 
In this paper, we report preliminary results showing that 
B K T is a strong inhibitor of rat brain nNOS, mainly because 
of its effects on the activation of nNOS by the C a 2 + / C a M 
system. Accordingly, it is a much less potent inhibitor of 
murine macrophage inducible iNOS. These results could ex-
plain some of the therapeutic effects of BKT. 
2. Materials and methods 
2.1. Chemicals 
[2,3,4,5-3H]L-Arginine hydrochloride (300 mCi/mmol) was pur-
chased from Dupont-NEN. NADPH came from Boehringer and tet-
rahydrobiopterin from Alexis Biochemicals. Dowex 50W-X8 was 
from Aldrich. L-Citrulline, L-arginine hydrochloride, TV-nitro-L-argi-
nine (N02Arg), dithiothreitol (DTT), calmodulin, bromocriptine, er-
gotamine and all other chemicals were purchased from Sigma Chem-
icals. RPMI 1640 and fetal calf serum (FCS) came from Gibco. 
ZsoBKT was prepared from BKT according to a described procedure 
[18]. 
2.2. Enzyme preparation 
Recombinant rat brain NOS (nNOS) was obtained from yeast Sac-
charomyces cerevisiae strain WKfurl transfected with a gene encoding 
the rat brain isoform following recently described procedures [19]. The 
A379 plasmid carrying the rat brain NOS cDNA was a generous gift 
from Prof. P.O. De Montellano (University of California, San Fran-
cisco, CA, USA). The culture procedures used to achieve nNOS ex-
pression in yeast are identical to those described in Sari et al. [19]. 
Neuronal NOS was purified through CaM-agarose affinity column 
chromatography (Pharmacia) as described [20] and was buffer-ex-
changed through a Sephadex G-50 column to 50 mM HEPES pH 
7.5 just before use. It appeared 95% pure from SDS-PAGE stained 
with Coomassie blue and displayed average Km and Vm values of 
8.0 ± 2.0 U.M and 350 ± 50 nmol L-cit min - 1 mg protein-1 respec-
tively. 
Murine macrophages were obtained from C3H/HeN mice injected 
intraperitoneally with thioglycolate broth (Institut Pasteur) 3 days 
before harvesting the cells. Adherent macrophages (3xl06 /ml in 
RPMI supplemented with 10% FCS) were incubated for 18 h at 
37°C with 10 ng/ml LPS under a 5% C0 2 humidified atmosphere. 
Activated macrophages were washed twice and put in fresh medium 
containing 2 mM L-arg and various concentrations of the studied 
compounds. Nitrite production [21] and cell viability [22] were meas-
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ured 24 h later following previously described methods. Inducible 
NOS (iNOS) was obtained from about 108 peritoneal murine macro-
phages and purified as described [23] onto a 2',5'-ADP-agarose affin-
ity column (Pharmacia). 
Protein concentrations were determined by the Bradford protein 
assay kit (Bio-Rad) using bovine serum albumin as standard. 
2.3. NOS activity assays 
2.3.1. [3H]'L-Citrulline formation. NOS-dependent oxidation of L-
arg to L-cit was determined according to a previously described tech-
nique [24]. Briefly, enzymatic reactions were conducted at 37°C for 5 
min in 50 mM HEPES (pH 7.5) containing 5 mM DTT, 50 uM L-arg, 
about 500000 cpm [2,3,4,5-3H]L-arg, 1 mM NADPH, 1 mM CaCl2, 
10 ug/ml CaM, 20 uM BH4, 4 uM FAD, 4 uM FMN, and the tested 
agents as indicated. Final incubation volumes were 100 ul. The reac-
tions were started by the addition of protein and terminated by the 
addition of 500 ul of cold stop buffer (20 mM sodium acetate pH 5.5, 
1 mM L-cit, 2 mM EDTA, and 0.2 mM EGTA). Samples (500 ul) 
were applied to columns containing 1 ml of Dowex AG 50W-X8 (Na+ 
form, prepared from the H + form), pre-equilibrated with stop buffer 
and a total of 1.5 ml of stop buffer was added to eluate [3H]L-cit. 
Aliquots were then counted on a Packard Tri-Carb 2300 liquid scin-
tillation spectrometer. Control samples without nNOS, CaM, or 
NADPH were included for background determinations. Activity of 
iNOS was determined similarly but CaCl2 and CaM were omitted. 
2.3.2. NADPH consumption by nNOS. The initial rates of 
NADPH oxidation were quantitated spectrophotometrically at 340 
nm using an extinction coefficient of 6.2 m M - 1 cm - 1 [14]. Cuvettes 
contained 1 ml of 50 mM HEPES, pH 7.4, 5 mM DTT, 1 mM CaCl2, 
500 |XM NADPH, 4 (xM FAD, 4 uM FMN, 20 uM BH4, and, when 
required, L-arg (1 mM), CaM (10 ug/mi) and the tested compounds. 
Incubations were run for 5 min at ambient temperature on a Kontron 
941 spectrophotometer and were initiated by the addition of nNOS. 
2.3.3. Cytochrome c reductase activity of nNOS. The initial rates 
of flavin dependent reduction of Cyt c by nNOS were quantitated 
spectrophotometrically at 550 nm, using an extinction coefficient of 
21 m M - 1 cm - 1 [14]. The reaction mixture (final volume 1 ml) con-
tained 50 mM HEPES pH 7.5 without DTT, 2 mM CaCl2, 100 uM 
NADPH and 40 (iM Cyt c. Some assays contained CaM (10 ug/ml) 
and the studied compounds as indicated. The reactions were run for 
5 min and were initiated by the addition of nNOS. 
3. Results 
BKT produced a concentration-dependent inhibition of the 
oxidation of [3H]L-arg by NADPH and 0 2 to [
3H]L-cit cata-
lyzed by recombinant nNOS purified from yeast expressing rat 
brain NOS (Fig. 2). As expected, this nNOS activity was sup-
pressed in the absence of CaM or in the presence of 25 u\M 
N02Arg, a well-known NOS inhibitor [9] (Table 1). IC50 val-
ues of 10.0 ±2.0 uM were obtained for BKT (Fig. 2). Inter-
estingly, the IC50 values were found to be dependent upon 
Bromocriptinc (RKT) 
iso Bromocriptinc (iso BKT) 
Ergotamine 
Rr = Br 
R | = Br 
R l = H 
R 2 = CH(CH3)2 
R 2 = CH(CH3)2 
R 2 = CH3 
R3 = CH(CH3)2 
R3 = CH(CH3h 
R 3 = C 6 H 5 
Fig. 1. Structures of BKT, woBKT and ergotamine. 
CaM concentrations (IC50 = 7.0± 1.0 uM, 10.0 ±2.0 uM, 
and 32.0 ±2.0 uM when using 1, 10 and 50 ug/ml CaM, re-
spectively). In addition, isoBKT, the C-8 epimer of BKT (Fig. 
1), was a less potent inhibitor than the parent BKT, with an 
IC50 value of 35 ±8 uM (Fig. 2). Another ergot alkaloid, 
ergotamine, was less active (IC50 = 50 ± 8 uM) (Table 1). 
The inhibitory effects of BKT towards iNOS purified from 
mouse macrophages were also investigated. BKT weakly in-
hibited L-cit formation catalyzed by purified iNOS (about 
20% inhibition at 100 |xM); moreover, BKT was almost with-
out effect on the formation of nitrite by LPS-stimulated 
mouse macrophages (less than 10% inhibition at 100 |J.M), 
whereas N02Arg strongly inhibited both iNOS activities (Ta-
ble 1). These results indicate a clear selectivity of BKT for 
nNOS (IC50 more than 10 times lower for nNOS than for 
iNOS). 
Double-reciprocal plots of the nNOS activity ([3H]L-cit for-
mation from [3H]L-arg) as a function of L-arg concentration 
showed that increasing concentrations of BKT caused a de-
crease of the Vm value without changing the Km value of L-
arg for nNOS (Fig. 3, for Km and Vm values, see Section 2). 
These results suggest that BKT was not a competitive inhib-
itor of the nNOS-dependent oxidation of L-arg. The lack of 
interaction of BKT at the L-arg binding site was confirmed by 
spectral studies showing that addition of increasing amounts 
(up to 50 uM) of BKT to nNOS failed to lead to any change 
of the visible spectrum of the heme. Furthermore, addition of 
BKT did not modify the Ks value of L-arg for nNOS (data 
not shown). 
As previously reported, nNOS catalyzed the oxidation of 
NADPH both in the presence and in the absence of L-arg, the 
Table 1 
Effect of BKT, isoBKT and ergotamine on the formation of [3H]L-cit from [3H]L-arg catalyzed by purified nNOS and iNOS, and on nitrite 
formation from LPS-activated murine macrophages 
Complete system (C.S.) 
- C a M 
+N02Arg (100 uM) 
+BKT (25 uM) 
+BKT (100 uM) 
+isoBKT (25 uM) 
+Ergotamine (25 uM) 
Activity (% C.S.)a 
nNOS 
100c 
< 1 
< 1 
31 ±8 
11 ±3 
53 ±5 
81 ±10 
iNOS 
100d 
ndf 
5 ± 2 
92±7 
80±6 
85±6 
nd 
mM(|>b 
100c 
nd 
17±3 
97±7 
93±7 
nd 
nd 
a[3H]L-cit formation was measured as described in Section 2. Results are expressed as means ± S.E.M. from 4-6 experiments. 
bmM(|>: LPS-activated murine macrophages. Specific activities for purified NOSs: cnNOS and diNOS: 350±50 and 80±20 nmol L-cit min - 1 
protein -1 respectively. 
eNitrite formation from LPS-stimulated murine macrophages: 35±3 umol/3x 106 cells/18 h. 
fNot determined. 
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A. Renodon et al.lFEBS Letters 406 (1997) 33-36 35 
1*1 
> 
u 
a 
-— « 
'5 
100 
80 
60 
40 
# 20 
10 
Concentration (u M) 
100 
Fig. 2. Effect of increasing concentrations of BKT and isoBKT on 
[3H]L-cit formation catalyzed by purified nNOS. Rates of oxidation 
of [3H]L-arg to [3H]L-cit were measured as described in Section 2 in 
the presence of increasing concentrations of BKT (■) or isoBKT 
(□). Activity in the absence of BKT (100%) was 350 ±50 nmol. L-
cit min-1 mg protein-1. Results are means ±S.E.M. from 4 experi-
ments. 
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Fig. 3. Double reciprocal plot of the nNOS activity ([3H]L-cit for-
mation) as a function of L-arg concentrations, in the presence of 
various concentrations of BKT. Oxidation of [3H]L-arg to [3H]L-cit 
was measured as described in Section 2 in the absence (□) or in the 
presence of 10 (■) or 25 uM (•) BKT. Activity expressed in nmol 
L-cit min-1 mg protein-1. Results are means ± S.E.M. from 3 deter-
minations. 
rate being two-fold higher in the absence of L-arg (Fig. 4) 
[15]. This reaction did not occur in the absence of CaM and 
was greatly inhibited by N02Arg (100 uM). BKT (10 and 50 
uM) inhibited the L-arg-dependent (Fig. 4, hatched bars) and 
the L-arg-independent (Fig. 4, open bars) oxidation of 
NADPH to almost similar extents. These results further con-
firmed that BKT did not simply interact with nNOS at the L-
arg binding site. 
The hypothesis of an interaction of BKT with the CaM-
dependent activation of nNOS was then tested by studying the 
effects of BKT on the nNOS-catalyzed reduction of Cyt c by 
NADPH. This reduction is much faster in the presence of 
CaM [14-17] as shown by the 15-fold stimulation of the ac-
tivity (2.90 ± 0.3 nmol instead of 0.18 ± 0.03 umol reduced Cyt 
c min- 1 mg protein-1) (Fig. 5). BKT only slightly decreased 
the CaM-independent activity whereas it strongly inhibited 
the CaM-dependent nNOS-catalyzed reduction of Cyt c 
(about 80% inhibition at 50 uM, Fig. 5). These results clearly 
show that BKT interfered with the CaM-dependent electron 
transfer from NADPH via the nNOS reductase domain. 
4. Discussion 
The present results show that BKT, and to a lesser extent 
isoBKT as well as some other ergot alkaloids (Boucher et al., 
in preparation), inhibits the various activities of nNOS. BKT 
inhibits the nNOS-dependent oxidation of L-arg (NO forma-
tion) with an IC50 value of 10 ±2 uM, a concentration of 
pharmacological relevance, mainly because it interferes with 
the necessary activation of nNOS by CaM. This explains the 
much higher inhibitory effects of BKT towards nNOS com-
pared to iNOS (either purified or in LPS-stimulated mouse 
macrophages), as iNOS is more tightly bound to CaM [11]. 
BKT could thus be compared to calmidazolium, to the anti-
psychotics trifmoperazine and chlorpromazine (IC50: 2, 7 and 
15 |J,M respectively) [25] and to the neuroleptic haloperidol 
(IC50: 31 uM) [26] which are potent CaM antagonists. These 
results reinforce previous studies which have suggested inter-
actions of BKT and other ergot alkaloids with CaM-depend-
ent proteins [1,6]. 
The strong inhibitory effects of BKT towards nNOS could 
be, at least in part, at the origin of some therapeutic effects of 
this drug. Protective effects of BKT in patients suffering from 
Parkinson's disease could be related to its ability to inhibit 
nNOS-dependent formation of NO, 02~ and H2O2 as well as 
of peroxynitrite, a product arising from reaction of NO with 
0'2~ which is involved in neurodegenerative diseases [27,28]. 
As far as the anti-migraine effects of BKT are involved, it has 
recently been shown that NO plays a key role in migraine 
[29,30]. Inhibition of nNOS-dependent formation of NO 
could thus participate in the anti-migraine effects observed 
with BKT and other ergot alkaloids. Finally, concerning the 
effects of BKT on prolactin secretion, it is noteworthy that 
several studies have established a link between NO and pro-
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Fig. 4. Effect of CaM, BKT and N02Arg on NADPH oxidation 
catalyzed by purified nNOS. NADPH oxidation was assayed as de-
scribed in Section 2. C.S.: complete system. Maximal activities were 
1020 ±110 and 475 ±70 nmol NADPH consumed min-1 mg 
protein-1 in the absence (open bars) and in the presence of L-arg (1 
mM, hatched bars). Experiments were performed in the absence of 
CaM (-CaM), in the presence of 10 or 50 11M BKT, or 100 uM 
N02Arg. Results are means ± SEM from 3 determinations. 
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Fig. 5. Effects of BKT on the reduction of Cyt c by NADPH cata-
lyzed by purified nNOS. Cyt c reduction was assayed as described 
in Section 2 without CaM (open bars) or in the presence of 10 u.g/ 
ml CaM (hatched bars). C.S.: complete system without BKT. BKT 
10 or 50: C.S. contained 10 or 50 uM BKT. Activities in nmol Cyt 
c reduced min - 1 mg protein -1. Results are means ±S.E.M. from 
3 determinations. 
lactin generation. For instance, treatments of rats with N O 
donor such as SIN-1 have recently been found to lead to an 
increase in plasma prolactin levels, whereas treatment with 
N 0 2 A r g completely suppressed the steroid-induced prolactin 
surge in rat [31-33]. It is thus tempting to propose that the 
action of BKT on prolactin secretion could be mediated by 
N O , or a NOS-derived product. In addition, some side effects 
of B K T such as post-partum hypertension or digestive dis-
eases [1] could be related to the effects of well known n N O S 
inhibitors, like N 0 2 A r g [9]. 
The relationships between the therapeutic effects of ergot 
alkaloids and N O formation require further detailed pharma-
cological investigations. 
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